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MMP14 encodes a membrane-tethered metallopro-
teinase MT1-MMP, capable of remodeling the extra-
cellular matrix and modulating receptors on the cell
surface. Loss of MT1-MMP results in craniofacial
abnormalities. Here we show that MT1-MMP forms
a complex with FGFR2 and ADAM9 in osteoblasts
and proteolytically inactivates ADAM9, hence pro-
tecting FGFR2 from ADAM9-mediated ectodomain
shedding on the cell surface. In Mmp14/ osteo-
blasts, FGF-induced proliferation and downstream
signaling are specifically compromised, in conjunc-
tion with ADAM9 upregulation and FGFR2 shedding.
The retarded parietal growth in Mmp14/ embryos
starts at 15.5 dpc, attributable to the impaired
FGFR2 signaling due to increased shedding medi-
ated by ADAM9. Adam9 depletion completely
rescues the defective FGFR2 signaling and largely
restores calvarial bone growth in Mmp14/
embryos. These data reveal a regulatory paradigm
for FGRF2 signaling and identify MT1-MMP as a crit-
ical negative modulator of ADAM9 activity to main-
tain FGFR2 signaling in calvarial osteogenesis.
INTRODUCTION
Fibroblast growth factor receptors (FGFRs) are critical for intra-
membranous ossification during skull development (Ornitz and
Marie, 2002), and the activating mutations in FGFR1 and
FGFR2 account for several human craniofacial diseases, such
as Pfeiffer syndromes, osteoglophonic dysplasia, Crouzon
syndrome, and Apert syndrome, etc., characterized by craniosy-
nostosis (Miraoui and Marie, 2010). The FGFR2 knockin mouse
model with human-activating mutations manifests similar calva-
rial phenotypes (Miraoui and Marie, 2010). Mutation or loss of
Fgfrl1 also leads to craniofacial dysplasia and skeletal abnormal-
ities (Catela et al., 2009; Sleeman et al., 2001; Trueb, 2011).1176 Developmental Cell 22, 1176–1190, June 12, 2012 ª2012 ElsevAlthough Fgfr1 and Fgfr2 knockouts are embryonic lethal
(Deng et al., 1994; Xu et al., 1998; Yamaguchi et al., 1994),
mice with conditional inactivation of FGFR2 during mesen-
chymal condensation leads to skeletal dwarfism and decreased
bone density (Yu et al., 2003). In line with these observations,
Fgf2 knockout mice show decreased bone mass and bone
formation (Montero et al., 2000), and loss of Fgf18 results in
impaired osteogenesis in calvarial osteogenesis (Liu et al.,
2002; Ohbayashi et al., 2002). These clinical and experimental
results reveal a critical role for FGF signaling in calvarial osteo-
genesis during development.
Functional diversity of FGFRs is regulated by the wide variety
of FGF ligands, difference in ligand binding affinity and speci-
ficity, as well as the alternative splicing of FGFRmRNAs (Powers
et al., 2000). In addition, ectodomain shedding of receptors by
metalloproteinases also regulates FGF signaling. For instance,
FGFR2 can be cleaved by ADAM9 (Peduto et al., 2005) and
ADAM15 (Maretzky et al., 2009a, 2009b), whereas FGFR1 has
been shown to be shed by MMP2 (Levi et al., 1996). Ectodomain
shedding could conceivably reduce the levels of cell surface
receptors and releases functional ligand binding domains to
the extracellular space to compete with cell surface ligand
binding, therefore blocking normal activation of intracellular
FGFR signaling.
MT1-MMP, a membrane-bound matrix metalloproteinase
encoded by MMP14, plays critical roles in various physiological
and pathological processes through pericellular proteolysis and
extracellular remodeling (Barbolina and Stack, 2008; Werb,
1997). MT1-MMP-deficient mice exhibit severe postnatal growth
retardation, calvarial defects, and premature death (Holmbeck
et al., 1999; Zhou et al., 2000). Careful examination of the pheno-
types in Mmp14/ mice reveals that many defects seem to be
FGF-signaling related. For example, Mmp14/ mice exhibit
defective secondary septa formation in lung (Oblander et al.,
2005), a phenotype also observed in mice with impaired FGF
signaling due to either a dominant-negative FGFR2 transgene
(Celli et al., 1998) or reduced expression of FGF10 (Ramasamy
et al., 2007). In addition, defective calvarial bone growth in
Mmp14/ mice is also observed in Fgf18-deficient mice (Liu
et al., 2002; Ohbayashi et al., 2002). Furthermore, Mmp14/
mice exhibit defective FGF2-induced corneal angiogenesisier Inc.
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potential role for MT1-MMP in FGFR signaling and raise the
questions as to whether defective calvarial development in
Mmp14/ mice is a consequence of impaired FGFR signaling.
In this study, we investigated how MT1-MMP regulates FGFR
signaling in calvarial osteogenesis.
RESULTS
Calvarial Defects in Mmp14 Null Embryos
Previous studies suggested that defective postnatal calvarial
bone growth in Mmp14/ mice is attributable to the defective
cartilage primordium removal and defective collagen degrada-
tion (Holmbeck et al., 1999, 2003, 2005). To understand if osteo-
genesis itself is defective in the absence of MT1-MMP, we
examined the calvarial development in Mmp14/ embryos
when cartilage primordium is normally present under the parietal
bones.Calvariae from18.5dpcembryoswere stainedwithAlcian
blue and alizarin red (Figure 1A) to highlight the cartilage andossi-
fied bone tissues. The sizes of all five calvarial bones from
Mmp14/ embryos were much smaller compared with those
in wild-types, and the unossified region, as well as the distance
between two opposing parietal bones (Figure 1A, orange and
green arrows) in Mmp14/ calvariae, was much wider than
that in controls, due to smaller parietal bones in mutants at this
developmental stage. The retarded calvarial osteogenesis in
Mmp14/ embryos was further demonstrated by radioactive
in situ hybridization (RISH) using mature osteoblast marker
osteopontin (Opn) riboprobe in parietal sections (Figure 1B)
showing much wider distance between two parietal bones. The
growth of parietal bones starts at 12.5 dpc, and histologically,
therewas no obvious observable difference in the size of the pari-
etal bones and the area of unossified region betweenMmp14/
mutants and wild-type embryos until 15.5 dpc (Figure 1C). To
understand the nature of the defects in Mmp14/ calvariae,
Cbfa1/Runx2, the key transcriptional factor regulating osteogen-
esis and a downstream target of FGF signaling, was examined by
RISH. As shown in Figure 1D,Cbfa1was colocalized withOc and
Opn throughout the developing parietal bone with a relatively
higher level at the osteogenic front at 16.5 dpc. Compared with
controls, the level of Cbfa1 in Mmp14/ calvariae was moder-
ately downregulated at the developing parietal bone front where
osteogenesis occurs. Although the expression patterns of Oc
and Opn inMmp14/ parietal bones were different from that in
wild-type, their levels did not differ significantly. BrdU pulse
labeling revealed significantly decreased proliferation in calvarial
osteoblasts in parietal bones from 16.5 dpcMmp14/ embryos,
compared with that in littermate controls (Figure 1E; p = 0.0011).
No significant difference in the calvarial osteoblast proliferation
was observed at 14.5 dpc.
Colocalization of MT1-MMP with Fgf Ligands
and Receptors during Parietal Bone Development
To assess whether defects in calvarial bone development were
Fgf-signaling related, we first examined if Mmp14 is coex-
pressed with Fgfs or Fgfrs in parietal bones during embryonic
development by RISH. At 14.5 dpc, the front of parietal bones
reached to the ½ position of the skull. The expression of
Mmp14 overlapped with that of Fgf2, Fgf18, Fgfr1c, Fgfr2c,Developmand Fgfr3c in parietal bone (see Figure S1A, panels A–H,
available online). At 16.5 dpc, the parietal bones grew to the 3/4
position of the skull (Figure S1B, panel A). Mmp14 was coex-
pressed with Fgf2, Fgf18, Fgfr1c, and Fgfr2c in the developing
parietal bones (Figure S1B, panels B–H). Fgfr2c was expressed
at a relatively higher level at the osteogenic front (Figure S1B,
panel G). At 18.5 dpc, the parietal bones grow to the apex of
the skull as shown by skeletal preparation and Opn in situ
hybridization (Figures 1 and S1C). Mmp14 was more prominent
at the osteogenic front (Figure S1, arrows) at 14.5 and 16.5 dpc.
Fgf2 and Fgf18 appear throughout the developing parietal bones
at 14.5 and 16.5 dpc with relatively higher level at the front of
osteogenesis, and are colocalized withMmp14. All four receptor
variants examined in this work were coexpressed with Mmp14,
Fgf2, and Fgf18 at the osteogenic front and the sutural
mesenchymal tissue at 18.5 dpc (Figure S1C, panels A–H).
These data were consistent with previous work on FGF expres-
sion (Rice et al., 2000). Collectively, these data indicated that
Mmp14 is coexpressed with Fgf2, Fgf18, Fgfr1, and Fgfr2 in
the developing parietal bones during calvarial osteogenesis.
Defective FGF2-Induced Proliferation and Signaling
in Mmp14–/– Calvarial Osteoblasts
Because FGF signaling is essential for the proliferation of calva-
rial osteoblasts (Li et al., 2010; Ohbayashi et al., 2002; Yu et al.,
2003), we performed an in vitro BrdU-labeling assay by various
growth factors (Figure 2A) to test whether the decreased osteo-
blast proliferation inMmp14/ calvariae was a consequence of
impaired FGF signaling. TGF-b, PDGF-AA, and VEGF did not
induce significant mitogenic response in either wild-type or
Mmp14/ osteoblasts. PDGF-BB and EGF induced the prolifer-
ation of wild-type andMmp14/ osteoblasts to a similar extent.
FGF2 and FGF18 stimulated the proliferation in both wild-type
and Mmp14/ osteoblasts. However, the percentage of prolif-
erating osteoblasts from Mmp14/ mutants was significantly
lower than that from wild-types, approximately 40% reduction
compared to wild-type osteoblasts in response to both
FGFs (19.8% in wild-types versus 12.1% in mutants for FGF2,
p = 0.024; 24.2% in wild-types versus 16.6% in mutants for
FGF18, p = 0.0012). These data suggest thatMmp14/ calvarial
osteoblasts have a specific defect in FGF-induced proliferation.
Therefore, the defective parietal bone growth could be a conse-
quence of defective response of osteoblasts to FGF signaling.
In osteoblasts, the FGF-initiated proliferation response is
mediated via the Frs2a and mitogen-activated protein kinase
(MAPK)/Erk1/2 pathway (Kim et al., 2003). Upon FGF2 stimula-
tion, shown in Figures 2B and 2C, phosphorylation of Erk1/2
and Frs2a in wild-type cells started 5 min after FGF2 stimulation,
peaked at about 10 min, and gradually faded away afterward. In
Mmp14/ osteoblasts, the phosphorylation of Erk1/2 and Frs2a
was significantly inhibited, though weak phosphorylation could
be detected up to 30 min. Similar to FGF2, FGF18-induced
Erk1/2 phosphorylation was also significantly compromised in
Mmp14/ osteoblasts (Figure 2D). The endogenous phosphor-
ylated Erk1/2 in Mmp14/ newborn parietal bone tissues
was also considerably lower than that in littermate controls
(Fiure 2E). Consistent with the compromised ErK1/2 phosphory-
lation, the transcription of Msx1 and Msx2, two downstream
targeting genes of FGF-signaling pathway critical for calvarialental Cell 22, 1176–1190, June 12, 2012 ª2012 Elsevier Inc. 1177
Figure 1. Calvarial Defects in Mmp14–/– Embryos
(A) Alcian blue and alizarin red staining of calvarial bones from 18.5 dpc embryos. The distance between two opposing parietal bones is indicated by orange
(controls) or green arrows (Mmp14/ mutants). Scale bars, 1 mm. I, interparietal bone; P, parietal bone; F, frontal bone; AR, anterior; PR, posterior.
(B) RISH for osteoblast marker Opn in 18.5 dpc parietal bone of wild-type (left) and Mmp14/ mutant (right). Scale bar, 5 mm.
(C) Skeletal preparation of calvarial bones from 15.5 dpc embryos. Red arrow bars represent the distance between opposing parietal bones in wild-type and
heterozygous embryos, whereas the green arrow bars represent that in Mmp14/ mutants. Scale bars, 1 mm.
(D) RISH of Cafa1/Runx2, Oc, and Opn transcript in coronal sections of parietal bones from 16.5 dpc embryos (right). The diagrams illustrate the plane of
sectioning (black dotted line, top left) and the view of pictures taken (bottom left). The red arrows indicate the osteogenic fronts. Scale bar, 5 mm. BR, cerebrum
cortex; S, Skin; I, interparietal bone; F, frontal bone.
(E) In vivo BrdU incorporation assay. Coronal sections of parietal bones from wild-type (top left) andMmp14/mutants (top right) at 16.5 dpc were stained with
BrdU antibodies. The percentage of BrdU-positive bone cells in sections from wild-type andMmp14/ embryos at different stages was calculated. At least 200
bone cells of each section were counted in each genotype. Data are presented as the average ± SEM (n = 3; ***p < 0.001) (bottom). BR, cerebrum cortex; CB,
calvarial parietal bone; S, Skin. Scale bar, 5 mm.
See also Figure S1.
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et al., 2000; Satokata and Maas, 1994), was significantly
decreased in Mmp14/ calvarial bone tissue measured by1178 Developmental Cell 22, 1176–1190, June 12, 2012 ª2012 Elsevquantitative reverse-transcription PCR (p = 0.015 for Msx1;
p = 0.035 for Msx2) (Figure 2F). Moreover, expression of three
other specific FGF responsive genes (Cabrita and Christofori,ier Inc.
Figure 2. Defective FGF Signaling in Mmp14–/– Calvarial Osteoblasts
(A) In vitro BrdU assay. Serum-starved calvarial osteoblasts were treated with different growth factors. Control cells were incubated with culture medium alone.
Data represent the average ± SEM (n = 3). *p < 0.05; **p < 0.01.
(B) Wild-type and Mmp14/ calvarial osteoblasts were serum starved prior to FGF2 treatment. Cells were treated with FGF2 for different times as indicated.
Phosphorylated and total Erk1/2 (pErk1/2 and tErk1/2) was detected in cell lysates by western blotting. a-Tubulin served as a loading control. Quantification of
Erk1/2 phosphorylation relative to total Erk1/2 is shown in lower panel (n = 3). *p < 0.05; **p < 0.01.
(C)Western blotting of pFrs2a of the same samples from (B). Quantification of Frs2a phosphorylation relative to a-tubulin is shown in lower panel (n = 3). *p < 0.05.
(D) Western blotting of Erk1/2 and MT1-MMP of serum-starved calvarial osteoblasts. Cells were treated with or without FGF2, FGF18 (30 ng/ml each) for 10 min
before harvest. Quantification of Erk1/2 phosphorylation relative to total Erk1/2 is shown in lower panel (n = 3). *p < 0.05; **p < 0.01.
(E) Western blotting of parietal bone lysates from newborn wild-type and Mmp14/ mice by antibodies against pERK1/2. Total Erk1/2 served as the loading
control. Quantification of Erk1/2 phosphorylation relative to total Erk1/2 is shown in lower panel (n = 3). **p < 0.01.
(F) Quantitative reverse-transcription PCR analyses of Msx1, Msx2, Spry2, Spry4, and Dusp6 mRNA expression in 18.5 dpc wild-type and Mmp14/ calvarial
bones. Data represent the average ± SEM (n = 3). *p < 0.05.
See also Figure S2.
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Spry4, and Dusp6, consistently decreased in Mmp14/ calva-
rial bone tissue (p = 0.011 for Spry2; p = 0.014 for Spry4;Developmp = 0.039 for Dusp6) (Figure 2F). These data indicated that loss
of MT1-MMP significantly and specifically impairs FGF-Frs2a-
MAPK-Erk1/2 pathway both in vitro and in vivo.ental Cell 22, 1176–1190, June 12, 2012 ª2012 Elsevier Inc. 1179
Figure 3. FGF2-Induced Ex Vivo Growth of Calvaria Explants Requires MT1-MMP
(A) Photograph of 15.5 dpc mouse head. To prepare the calvarial explant, upper part of the skull was dissected from the white line toward the back (white arrow).
(B) A cartoon diagram illustrates the calvarial explant. Beads (circle dots) soaked with BSA or FGF2 were placed at the osteogenic fronts of the parietal bones.
I, interparietal bone; P, parietal bone; F, frontal bone.
(C) Ex vivo calvarial culture for 72 hr in the presence or absence of FGF2. Control calvarial explants were cultured alone (A–D) or with BSA-soaked beads (E–H).
Mmp14/ calvarial explants were cultured in the presence (Q–T) or absence (M–P) of FGF2. Control parietal bones grew to the same extent after 72 hr in the
presence and absence of BSA-soaked beads (red and blue arrows). The growth of control parietal bones was accelerated in the presence of FGF2-soaked beads
(I–L) (black and blue arrows). FGF2 did not stimulate the growth ofMmp14/ calvarial explants (Q–T), compared with those without FGF2 (M–P). The osteogenic
fronts of parietal bones are outlined by red dotted lines. Scale bar, 5 mm.
(D) Quantification of parietal bone growth in the presence and absence of FGF2 fromMmp14/ and control calvariae. Data represent the average ± SEM (n = 5).
***p < 0.001.
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Requires MT1-MMP
To further address if impaired FGF signaling is responsible for
defective osteogenesis in Mmp14/ calvariae, we examined
the ex vivo calvarial bone growth in the presence and absence
of FGF ligand because exogenous FGF2 can accelerate the1180 Developmental Cell 22, 1176–1190, June 12, 2012 ª2012 Elsevgrowth of parietal bones ex vivo (Kim et al., 1998, 2003). Heparin
beads soakedwith FGF2 or BSAwere applied locally at the oste-
ogenic fronts on parietal bones of 15.5 dpc calvariae (Figure 3).
Parietal bone growth was not affected by beads or BSA. The
growth of wild-type parietal bones was significantly accelerated
upon the stimulation of FGF2 (Figure 3C, panels I–L, andier Inc.
Figure 4. Increased Accumulation of a Truncated
FGFR2 Fragment in Calvarial Osteoblasts and
Tissues from Mmp14–/– Mice
(A) Western blotting of FGFR2 using antibodies against
C terminus of FGFR2 in wild-type andMmp14/ calvarial
osteoblasts. The black arrow indicates a truncated form of
FGFR2 (60 kDa). b-Actin served as the internal loading
control.
(B) Western blotting of FGFR2 using antibodies against
C terminus of FGFR2 in wild-type andMmp14/ calvarial
osteoblasts transfected with either control siRNA or
FGFR2 siRNA.
(C) Western blotting of FGFR2 in parietal bones from
newborn wild-type and Mmp14/ mice using antibodies
against C terminus of FGFR2.
(D) Biotinylated cell surface FGFR1 and FGFR2 detected
by western blotting in wild-type and Mmp14/ calvarial
osteoblasts (left). Quantification of cell surface FGFR2
relative to Coomassie blue-stained control is shown in
the right panel. Data represent average ± SEM (n = 3).
*p < 0.05.
(E) Western blotting of MT1-MMP and FGFR2. C-terminal
Flag-tagged FGFR2 was cotransfected with either EV, or
FL, or cytosolic tail deleted MT1-MMP cDNA (dC) or
activity-deadmutantMT1-MMP cDNA (EA) intoMS1 cells.
Total cell lysates were subjected to western blotting using
anti-flag antibody. a-Tubulin served as the loading control.
See also Figure S3.
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panels A–D, and Figure 3C, panels E–H). However, FGF2 did
not accelerate the parietal bone growth in Mmp14/ calvariae
(Figure 3C, panels M–P, and Figure 3D). After 72 hr, the distance
between two parietal bones inMmp14/ calvariae treated with
FGF2 was significantly longer than that in wild-type calvariae
with or without FGF2 (Figure 3C, panels Q–T, and Figure 3D).
Exogenous FGF2 had little, if any, effect on ex vivo bone growth
inMmp14/ parietals, suggesting that defective parietal growth
does not result from compromised ligand availability. This was in
line with the defective response of primary Mmp14/ osteo-
blasts to FGFs.
Accumulation of Truncated Form of FGFR2 due
to MT1-MMP Deficiency
FGF signaling is tightly controlled by the availability of FGF
ligands, heparin sulfate proteoglycans, HSPG and receptor
specificity of the splicing variants of FGFRs, and receptor ecto-
domain shedding by metalloproteinases. To test whether defec-
tive FGF signaling inMmp14/ osteoblasts is a result of altered
FGFR expression, we examined FGFRs by western blotting.
Interestingly, reduced full-length FGFR2 together with increasedDevelopmental Cell 22, 117accumulation of a ‘‘truncated’’ FGFR2 fragment
with an estimated molecular weight of 60 kDa
were observed in primary Mmp14/ osteo-
blasts by western blotting using antibodies
against C terminus of FGFR2, compared to
wild-type osteoblasts (Figure 4A). Knockdown
of FGFR2 by siRNA in Mmp14/ osteoblasts
significantly reduced the expression of FGFR2
and efficiently eliminated the truncated FGFR2,indicating the specificity of the antibodies to truncated
FGFR2 (Figure 4B). No significant difference in other FGFRs
(FGFR1, FGFR3, and FGFR4) was observed between wild-type
and Mmp14/ parietal bones by western blotting (Figures S2A
and S2B). The accumulation of truncated FGFR2 was also
detected in calvarial bone tissues from Mmp14/ newborn
mice (Figure 4C), suggesting that the accumulation of truncated
FGFR2 after MT1-MMPdepletion also occurs in vivo. The forma-
tion of truncated FGFR2 raises the possibility that loss of MT1-
MMP may affect the cell surface level of FGFR2. We therefore
examined the cell surface FGFR1/FGFR2 in calvarial osteo-
blasts, detected by cell surface protein biotinylation. Cell surface
FGFR2, but not FGFR1, was specifically reduced in Mmp14/
osteoblasts by about 40% (p = 0.021) (Figure 4D).
To substantiate this observation, Flag-tagged FGFR2 was
ectopically expressed in MS1 cells together with either empty
vector (EV), full-length MT1-MMP cDNA (FL), C-terminal cyto-
plasmic tail deletedMT1-MMPcDNA (dC), or enzymatically inac-
tive E240A mutant MT1-MMP (EA). Consistent with what we
observed in osteoblasts and calvariae, accumulation of trun-
cated FGFR2 fragment similar in size was observed in EV-trans-
fected cells where MT1-MMP was undetectable. Similarly, the6–1190, June 12, 2012 ª2012 Elsevier Inc. 1181
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cotransfected with either active site mutant MT1-MMP (EA) or
C-terminal deleted MT1-MMP. This specific truncated FGFR2
fragment was not detectable in cells cotransfected with full-
length wild-type MT1-MMP cDNA (Figure 4E). These data
confirmed that the truncated fragment detected in Mmp14/
osteoblasts indeed is FGFR2 fragment, and MT1-MMP activity
is required for protecting FGFR2 from shedding.
We next tested if MT1-MMP is required for FGF2-FGFR
signaling by examining the Mmp14 transcript upon FGF2
stimulation. By quantitative reverse-transcription PCR, we found
that Mmp14 mRNA in wild-type primary calvarial osteoblasts
increased by 60% upon FGF2 (30 ng/ml) stimulation for 30 min
(p = 0.047) (Figure S2C), suggesting that FGF2-FGFR signaling
can induce the expression of MT1-MMP, which may be neces-
sary for sustained FGF signaling.
To provide further evidence for the involvement of MT1-MMP
in FGF signaling in osteogenesis, we examined the endogenous
interaction between MT1-MMP and FGFR2 in primary calvarial
osteoblasts. As shown in Figure S2D, MT1-MMP was detected
from FGFR2 immunoprecipitation, and reciprocally, FGFR2
was detected in MT1-MMP immunoprecipitation. This is consis-
tent with our recent observation in tumor cells with ectopic MT1-
MMP and FGFR2 (Sugiyama et al., 2010).
ADAM9 Is Responsible for the Accumulation
of Truncated FGFR2 and Subsequent Defective
FGF2-FGFR Signaling
Because ADAM9 is able to process FGFR2 at the ectodomain
and the estimated size of the ectodomain fragment of FGFR2
released from Mmp14/ osteoblasts (deduced from the size
of C-terminal truncated FGFR2 fragment) is similar to that shed
by ADAM9 (Peduto et al., 2005), we examined ADAM9 expres-
sion to test if the increased accumulation of truncated FGFR2
resulting from loss of MT1-MMP could be related to altered
ADAM9 function. Indeed, ADAM9 was significantly upregulated
in primary Mmp14/ calvarial osteoblasts (Figures 5A and 5B)
(p = 0.001) and in Mmp14/ calvarial bone tissues (Figure 5C),
whereas Adam9 transcription was not affected by the loss of
MT1-MMP (Figure S4A). In addition, knocking down Adam9 in
Mmp14/ calvarial osteoblasts eliminated truncated FGFR2
(Figure S5A). These data suggested that the upregulated
ADAM9 in Mmp14/ osteoblasts could be a consequence of
decreased proteolytic processing of ADAM9 protein by MT1-
MMP. The elevated ADAM9 protein expression in the absence
of MT1-MMP was further evident by double staining of ADAM9
and MT1-MMP in parietal bones from newborn mice (Figure 5D).
Consistent with RISH results (Figure S1C), immunofluorescence
staining showed that MT1-MMP was highly expressed in the
osteogenic front and in the suture where ADAM9 was barely
detectable in wild-type parietal bones. Weak staining of
ADAM9 protein was found to colocalize with MT1-MMP only in
regions where MT1-MMP expression declined (Figure 5D, left).
However, strong staining of ADAM9 was found throughout the
midsutural mesenchyme and the calvarial bone tissues in
Mmp14/ newborn mice (Figure 5D, right). As the negative
controls, ADAM9 and MT1-MMP could not be detected in
Adam9/ parietal bone and Mmp14/ parietal bone, respec-
tively (Figures 5D and S4B), indicating that the signals are1182 Developmental Cell 22, 1176–1190, June 12, 2012 ª2012 Elsevspecific for ADAM9 and MT1-MMP, respectively. These results
suggested that MT1-MMP may proteolytically eliminate
ADAM9 and raised the possibility that compromised FGF
signaling in Mmp14/ calvariae is a direct consequence of up-
regulated ADAM9.
To test if increased ADAM9 activity compromises FGFR2
signaling, HEK293 cells stably expressing FGFR2 were trans-
fected with either EV, or wild-type or catalytically inactive mutant
(EA) ADAM9. Truncated FGFR2 was observed in cells trans-
fected with wild-type ADAM9, but not in those with inactive
mutant ADAM9 (Figure 5E). In line with this, cells transfected
with wild-type ADAM9 showed reduced pErK1/2 in response
to FGF2 as compared to controls or cells expressing mutant
ADAM9, suggesting that elevated ADAM9 is responsible for
the increased cleavage of FGFR2 and the defective FGFR
signaling (Figure 5E). Interestingly, serum stimulation did not
cause much difference in pERK1/2 between ADAM9 expressing
cells and controls or cells expressing mutant ADAM9, suggest-
ing that upregulation of ADAM9 specifically compromises FGF-
induced ERK1/2 phosphorylation. In addition, the regulation of
FGFR2 signaling by ADAM9 activity was also supported by the
endogenous interaction between FGFR2 and ADAM9 in wild-
type primary calvarial osteoblasts (Figure 5F).
MT1-MMP-Mediated ADAM9 Shedding Inactivates
ADAM9
To test if MT1-MMP facilitates ADAM9 inactivation, we trans-
fected either wild-type or activity-dead mutant MT1-MMP
into HEK293 cells stably expressing C-terminal Flag-tagged
ADAM9. Western blotting using antibodies against ectodomain
of ADAM9 detected a fragment (around 26 kDa) of ADAM9 in
the conditioned culture medium from cells cotransfected with
wild-type MT1-MMP, but not in that with catalytic activity-
dead MT1-MMP (Figure 6A, top). Consistent with this, both
proADAM9 zymogen and active ADAM9 in total cell lysate
were significantly decreased by western blotting using
antibodies against ADAM9 or Flag epitope tag (Figure 6A). In
addition, two additional C-terminal fragments of ADAM9 with
molecular weight of about 40 and 58 kDa were detected by
Flag antibodies only in cells expressing wild-type MT1-MMP,
representing the C-terminal fragments of cleaved ADAM9 (Fig-
ure 6A, middle, overexposure). Similarly, when primary osteo-
blasts were examined, ADAM9 was significantly upregulated in
Mmp14/ osteoblasts compared to wild-type cells (Figure 6B).
The 26 kDa ectodomain fragment of ADAM9 was also detected
in the conditioned culture medium from wild-type osteoblasts,
but not in that fromMT1-MMP-deficient osteoblasts (Figure 6B).
Consistently, no additional fragments of ADAM9 were detect-
able in cell lysates using antibodies against N terminus of
ADAM9. These data suggest that MT1-MMP promotes ADAM9
shedding to eliminate active ADAM9 on cell surface.
The potential cell surface shedding of ADAM9 by MT1-MMP
was further supported by the coIP results showing the endoge-
nous interaction between ADAM9 and MT1-MMP in primary
wild-type calvarial osteoblasts (Figure 6C) and in HEK293 cells
ectopically expressing ADAM9 and MT1-MMP (Figure S4C). In
the primary calvarial osteoblasts, mature form of MT1-MMP
associates with the active form of ADAM9 that is predominantly
expressed. However, in HEK293 cells in which MT1-MMP andier Inc.
Figure 5. Upregulation of ADAM9 in Mmp14–/– Mice
(A) Western blotting of ADAM9 in wild-type andMmp14/ calvarial osteoblasts (each lane represents an independent embryo). a-Tubulin served as the loading
control.
(B) Relative level of ADAM9 protein determined by normalizing the intensity of ADAM9 band against that of a-tubulin in western blotting. Data represent the
average ± SEM in calvarial osteoblast derived from four wild-type mice and three Mmp14/ mice. **p < 0.01.
(C) Western blotting of ADAM9 from two pairs of wild-type and Mmp14/ calvarial bones using antibodies against N terminus of ADAM9. a-Tubulin served as
a loading control.
(D) Localization and expression of ADAM9 and MT1-MMP by immunofluorescence staining in parietal bones. The plane of sectioning is similar to that shown in
Figure 1D. Coronal sections of parietal bones fromWT (left) andMmp14/ (right) newbornmice were examined using specific antibodies against ADAM9 (green)
and MT1-MMP (red). The left upper-corner insets of each image (I–VIII) show the higher magnification of the boxed area. Merged images showed the coloc-
alization of MT1-MMP and ADAM9. Adjacent sections of parietal bones were stained by H&E to show the histology. The osteogenic fronts are indicated by black
arrows, and the suture is located in between two arrows. Immunofluorescence staining on the coronal sections of parietal bones from Adam9/ newborn mice
served as a control for the specificity of ADAM9 staining and is shown in Figure S4C. The same images of WT parietal bones with higher magnification are shown
in Figure S4C for comparison. Scale bars, 500 mm.
(E) Western blotting of MT1-MM, ADAM9, Erk1/2, and FGFR2. Total Erk1/2 served as a loading control. The truncated form of FGFR2 (indicated by arrow) was
detected by antibodies specifically recognizing C terminus of FGFR2. Phosphorylation of Erk1/2 was examined in response to serum/FGF2 stimulation.
Quantification of pErk1/2 versus total Erk1/2 is shown in lower panel (n = 3). *p < 0.05.
(F) ADAM9 and FGFR2 coIPs. Lysates fromwild-type calvarial osteoblasts were incubated with anti-ADAM9 antibodies and anti-FGFR2 antibodies, respectively,
followed by western blotting (IB) using antibodies indicated.
See also Figure S4.
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Figure 6. MT1-MMP Sheds ADAM9 to Protect FGFR2 from Cleavage
(A) HEK293 cells expressing C-terminally Flag-tagged ADAM9 were transfected together with either wild-type or E/A mutant MT1-MMP (MT1 EA). Western
blotting of conditioned media and total cell lysates was performed using antibodies indicated. The N terminus and C terminus of ADAM9 were detected by
antibodies specifically recognizing N-terminal ADAM9 and Flag-tag, respectively. Arrows indicate two cleaved fragments of ADAM9 after extended exposure
(58 and 40 kDa).
(B) MT1-MMP sheds ADAM9 in primary calvarial osteoblasts. Conditioned media and total cell lysates from wild-type andMmp14/ calvarial osteoblasts were
subjected to western blotting using antibodies indicated.
(C) CoIPs of MT1-MMP and ADAM9. MT1-MMP and ADAM9 immunoprecipitations (IP) were prepared from wild-type calvarial osteoblasts lysates using anti-
bodies against MT1-MMP and ADAM9, respectively, and then subjected to western blotting (IB) using antibodies indicated. IgG immunoprecipitation served as
controls.
(D) MT1-MMP inactivates ADAM9 to inhibit ADAM9-mediated FGFR2 shedding. HEK293 cells stably expressing FGFR2 were transfected with either EV, or
ADAM9 alone, or wild-type MT1-MMP together with ADAM9, and MT1 EA together with ADAM9. Conditioned media (CM) and total cell lysates (CL) were
subjected to western blotting using antibodies indicated. The truncated form of FGFR2 is indicated by black arrow.
(E) Predicted cleavage sites of ADAM9 by MT1-MMP.
See also Figure S4.
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could be pulled down by antibody against MT1-MMP. To test
whether MT1-MMP, ADAM9, and FGFR2 form a tertiary
complex, we performed two-step coIP in HEK293 cells overex-
pressing three proteins (Figure S4D). Flag-tagged ADAM9
protein complex was first immunoprecipitated by M2 beads
(flag antibody-tagged beads) and eluted by flag peptides.
MT1-MMP and FGFR2 could be pulled down in the first immuno-
precipitation (Figure S4D, top). The eluted ADAM9 complex was
subject to the second immunoprecipitation by antibodies
against either FGFR2 or MT1-MMP. Either FGFR2 or MT1-
MMP could be detected in the second reciprocal coIP experi-
ment (Figure S4D, bottom). The presence of FGFR2/MT1-MMP
complex in the eluted ADAM9 protein complex suggested that
ADAM9 forms a tertiary complex with MT1-MMP and FGFR2.
When both ADAM9 and MT1-MMP were expressed in HEK293
cells with stable ectopic FGFR2, once again the expression of
wild-type but not the mutant MT1-MMP resulted in cleavage of
ADAM9 and reduction in pro and active ADAM9 (Figure 6D).
Importantly, ectopic wild-typeMT1-MMP prevented the produc-
tion of the specific truncated FGFR2 fragment generated by
ADAM9 (Figure 6D). Based on the estimated sizes of the ectodo-
main fragments released to culture medium and C-terminal
cleaved domains detected by western blotting after deglycosy-
lation treatment by PNGase F (Figures 6A, 6B, and S4E), two
potential cleavage sites on ADAM9 were predicted at the metal-
loproteinase and disintegrin domains, respectively (Figure 6E).
Together, these data demonstrated that MT1-MMP promotes
the cell surface shedding of ADAM9 to inactivate ADAM9
activity, thus protecting FGFR2 from proteolytical cleavage.
Loss of MT1-MMP resulted in elevated level of ADAM9 activity
and increased FGFR2 ectodomain shedding, leading to defec-
tive FGFR2 signaling in calvarial osteoblasts.
Removal of ADAM9 Restores FGFR Signaling
and Rescues the Retarded Calvarial Osteogenesis
inMmp14–/– Mice
To test if upregulated ADAM9 is responsible for defects
in Mmp14/ calvariae, we crossed Mmp14+/ mice with
Adam9/mice, followed by repeated interbreeding, to generate
Mmp14//Adam9/ compound mutant mice. The life span of
the double-knockout mice was not significantly extended,
though they survived a few days longer than Mmp14/ litter-
mates. Calvarial development of the compound mutant mice in
the late embryonic stage was examined. Compared with wild-
type calvariae, consistent defects were observed in Mmp14/
calvariae at 18.5 dpc. However, the sizes of all five calvarial
bones and the skulls of Mmp14//Adam9/ mice were
comparable to that in wild-type littermates and significantly
larger than those in Mmp14/ littermates (Figures 7A and 7B).
The rescue of calvarial phenotype was Adam9 dosage
dependent because heterozygosity of Adam9 already exhibited
significant rescue in the sizes of all five calvarial bones, and
homozygous loss of Adam9 essentially restored the calvarial
bone growth inMmp14/ embryos. At postnatal day 5, the pari-
etal defects in Mmp14/ mice were also significantly rescued
by the loss of Adam9 (Figure S5C). The skulls in double mutants
were similar in size to that of wild-type mice, and the sagittal
suture was significantly narrower than that in Mmp14/ mice,Developmthough still considerably wider than that in wild-typemice. These
data suggest that ADAM9 upregulation plays a predominant role
in defective calvarial osteogenesis in Mmp14/ embryos,
whereas during postnatal stage, MT1-MMP contributes to the
parietal growth in both ADAM9-dependent and ADAM9-inde-
pendent manners.
Because failure to remove the cartilage primordium under
calvarial bones has previously been proposed to be responsible
for the defective calvarial bone growth in Mmp14/ mice
(Holmbeck et al., 1999, 2003), we examined if the partial rescue
of calvarial defects in double-knockout mutants was a result
of successful removal of cartilage primordium. As shown in Fig-
ure S6, cartilage primordium under parietal bones was gradually
removed and replaced by ossified tissues in 5-day-old wild-type
calvariae. However, cartilage removal did not occur in either
MT1-MMP-deficient mice or Mmp14//Adam9/ littermates,
suggesting that cartilage primordium removal is exclusively
dependent on MT1-MMP, and partial rescue of calvarial bone
growth during postnatal development in double-mutant mice is
not a consequence of successful cartilage removal or collagen
degradation but a result from the loss of ADAM9, which likely
restores FGFR2 signaling. The existence of cartilage was likely
attributable to the Adam9-independent yet MT1-MMP-depen-
dent mechanism during postnatal development in Mmp14//
Adam9/ mice. The largely rescued calvarial osteogenesis in
Mmp14//Adam9/ embryos, however, suggests that MT1-
MMP-dependent cartilage removal and collagen degradation
may not play a significant role in calvarial osteogenesis and
may not account much for the retarded calvarial growth in
Mmp14/ mutants during embryonic development.
We then tested whether loss of Adam9 rescues FGF-FGFR
signaling in Mmp14/ calvarial bones. As shown in Figure 7C,
the cleaved FGFR2 fragment was observed only in Mmp14/
calvarial osteoblasts but was hardly seen in the compound
mutant or wild-type cells, suggesting that loss of Adam9 pre-
vented FGFR2 from shedding inMmp14/ calvarial osteoblasts
(Figure 7C, left). Similarly, depleting Adam9 significantly reduced
the truncated FGFR2 fragment in Mmp14/ calvarial bones
(Figure 7C, right). Consistently, loss of Adam9 restored the
ErK1/2 phosphorylation in Mmp14//Adam9/ calvarial
tissues and osteoblasts to the level similar to that in wild-type
calvariae (Figures 7D and S5D) and osteoblasts (Figures 7E
and S5E). Defective phosphorylation of Frs2 was also restored
in Mmp14//Adam9/ calvarial osteoblasts (Figures 7E and
S5E). Moreover, the proliferation rate of primary calvarial osteo-
blasts fromMmp14//Adam9/mice was completely restored
in response to FGF2 (30 ng/ml), determined by MTT assay (Fig-
ure 7F). The rescue of FGF signaling-dependent calvarial defects
inMmp14/ embryos by Adam9 depletion was further demon-
strated in the ex vivo calvarial culture system (Figure 7G). Again,
beads soaked with 30 ng/ml of FGF2 significantly accelerated
the growth of E16.5 parietal bones from wild-type embryos but
had little effect on those from Mmp14/ littermates. Calvarial
bones from Mmp14//Adam9/ embryos responded well to
FGF2 beads. The distance between two parietal bones was
significantly shortened in double mutants compared with that
inMmp14/ mutants 2 days after FGF2 incubation, though still
slightly longer than that in wild-types. Taken together, these
results demonstrated that loss of Adam9 restores the defectiveental Cell 22, 1176–1190, June 12, 2012 ª2012 Elsevier Inc. 1185
Figure 7. Adam9 Deletion Rescues the Defective Calvarial Osteogenesis in Mmp14–/– Mice and Restores FGF Signaling
(A) Alcian blue and alizarin red staining of calvariae from 18.5 dpc embryos. Scale bars, 5 mm.
(B) The skull size (top) and percentage of calvarial unossified area over the whole skulls (bottom). The circumference of 18.5 dpc calvariae was outlined, and the
outlined area representing skull size and unossified area as shown in Figure S5B were measured by ImageJ. Data represent the average ± SEM (n = 3 for wild-
type, n = 4 for each of the other genotypes). ***p < 0.001.
(C) Western blotting of FGFR2 in calvarial osteoblasts and in calvarial tissues from newborn mice. Arrows indicate the truncated form of FGFR2 detected by
specific FGFR2 antibodies.
(D) Western blotting of parietal bone lysates from newborn mice using antibodies indicated. Total Erk1/2 served as a loading control. Quantification of pErk1/2
versus total Erk1/2 is shown in Figure S6C.
(E) Western blotting of serum-starved calvarial osteoblasts followed by 10 min treatment with either FGF2 (30 ng/ml) or PBS. Total cell lysates were used for
western blotting using indicated antibodies. Quantification data are shown in Figure S6D.
(F) Primary calvarial osteoblast proliferation measured by MTT assay. Data represent average ± SEM (n = 3). **p < 0.01.
(G) Ex vivo calvarial culture. Calvarial explants obtained from 16.5 dpc embryos were cultured with FGF2-soaked beads. Pictures were taken at different time
points (0–48 hr) following FGF2 treatment. The distance between two parietal bones at the beginning of culture is indicated by blue arrow inMmp14/ embryo,
black arrow in wild-type, and red arrow in Mmp14//Adam9/ embryos. The distances between opposing parietal bones after 48 hr are indicated by green
arrow inMmp14//Adam9/ embryos and yellow arrow inMmp14/ embryos. The osteogenic fronts of parietal bones are outlined by red dotted lines. Scale
bar, 5 mm.
See also Figures S5 and S6.
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MT1-MMP Cleaves ADAM9 to Modulate FGF Signalingresponse to FGF signaling in Mmp14/ calvarial osteoblasts
and largely rescued the impaired calvarial osteogenesis in
Mmp14/ embryos. The results thus identify a critical role for
MT1-MMP in regulating ADAM9 activity and FGFR2 signaling
in calvarial bone development.
DISCUSSION
This study investigated the nature of the defects in calvarial
bones in Mmp14/ embryos. We demonstrated that defective
calvarial osteogenesis is a consequence of compromised
FGFR2 signaling mediated by abnormally upregulated ADAM9
activity. Calvarial bone defects in Mmp14/ mice were
FGF-signaling dependent because the mitotic responses of
Mmp14/ calvarial osteoblasts to FGF2 and FGF18 were
specifically compromised, and the FGF signal targeting genes,
including Msx1, Msx2, Spry2, Spry4, and Dusp6, were also
significantly downregulated in Mmp14/ calvarial bones.
Msx1 and Msx2 are also downstream targets of BMP signaling
(Kim et al., 1998; Satokata and Maas, 1994). However, BMP
signaling, detected by phosphorylation of Smad1/Smad5/
Smad8, was increased in calvarial bone tissues of Mmp14/
mice (Figure S2E). This suggests that the reduced expression
in Msx1/Msx2 in Mmp14/ calvarial bones is likely the conse-
quence of decreased FGF signaling because BMP signaling
positively regulates Msx expression in calvarial osteogenesis
(Kim et al., 1998; Satokata and Maas, 1994). Our data are
in line with a recent finding showing conditional loss of Fgfr1
in Axin2-positive cells enhances BMP signaling in cranial
suture (Maruyama et al., 2010). FGFR2-/Erk1/2 signaling was
recently shown to be dependent on metalloproteinase-mediated
EGFR transactivation in keratinocytes migration and regenera-
tive lung alveolarization (Ding et al., 2011; Maretzky et al.,
2011). However, this FGFR2/EGFR-signaling crosstalk unlikely
plays a significant role in MT1-MMP-dependent calvarial
development because the cranial phenotypes resulting from
loss of EGFR are completely different from those observed
in Mmp14/ mice (Holmbeck et al., 1999; Miettinen et al.,
1999; Schneider et al., 2009). In addition, AG1478, a specific
inhibitor for EGFR, failed to affect the FGF2-induced Erk
phosphorylation in primary calvarial osteoblasts (Figure S3A),
which further argues against the involvement of EGFR transacti-
vation in FGFR2/Erk1/2-signaling cascade, at least in calvarial
osteogenesis.
ADAM9 is widely expressed in the developing mesenchyme
and osteogenic tissues (Weskamp et al., 2002). ADAM9 has
been shown to shed FGFR2 at the juxtamembrane domain
between the IgIII domain and transmembrane domain (Peduto
et al., 2005). Despite the expression in osteogenic tissues, loss
of Adam9 does not seem to result in obvious histopathological
defects in bone development (Weskamp et al., 2002), though
elevated expression of ADAM9 has been reported to promote
cancer progression and metastasis in various cancers (Peduto,
2009). When overexpressed in prostate epithelium, ADAM9
transgenic mice exhibit a remarkable similarity in the formation
of disorganized prostatic ducts with mice expressing domi-
nant-negative FGFR2IIIb in prostate (Foster et al., 2002; Peduto
et al., 2005), suggesting a potential regulatory role for ADAM9 in
FGF signaling.DevelopmInterestingly, loss of Mmp14 leads to increased ADAM9 at
protein level (Figure 5), suggesting that the misregulated
FGFR2 signaling in Mmp14-deficient osteoblasts may be medi-
ated by elevated ADAM9 activity. Pro-MMP2 is activated by
MT1-MMP and has been shown to shed FGFR1 in vitro (Levi
et al., 1996). However,Mmp2 null mice only exhibit mild skeletal
abnormalities in the calvariae that are completely different from
those in Mmp14/ mice (Inoue et al., 2006; Mosig et al.,
2007). In addition, no abnormally processed FGFR1 fragment
similar to FGFR2 was found in Mmp14/ mice (Figures S2A
and S2B). On the other hand, impaired activation of pro-MMP2
in Mmp14/ mice would lead to increased FGFR signaling,
which is contradictory to the defective FGFR signaling in
Mmp14/ calvariae, therefore excluding the possible involve-
ment of MMP2-modulated FGFR1 signaling in the defective
FGF signaling and impaired calvarial osteogenesis inMmp14/
calvariae.
The defective calvarial bone development and increased
accumulation of a specific truncated FGFR2 fragment in
Mmp14/ mice suggest an important paradigm of FGFR-
signaling regulation mediated by MT1-MMP. ADAM9 cleaves
FGFR2 (Peduto et al., 2005) and releases the ectodomain frag-
ment that could jeopardize FGF signaling because FGFR2b ec-
todomain transgenic mice exhibited skeletal defects in both
long bones and the skull (Celli et al., 1998). It is possible that
the released ectodomain fragment of FGFR2 is functionally
active in vivo to jeopardize FGF signaling in the Mmp14/
mice. Because ADAM9-mediated shedding of FGFR2 could
significantly reduce the cell surface presentation of FGFR2 (Fig-
ure 4), compromised FGFR2 signaling in MT1-MMP null calvarial
osteoblasts may also be attributable to the reduced signal
perception of FGFR2 on the cell surface. In fact, recent studies
demonstrated a similar regulatory mechanism for TGF-b
signaling in which TACE/ADAM17 inhibits TGF-b signaling by
shedding type 1 TGF-b receptor (TbR-I), resulting in reduced
cell surface presentation of TbR-I and formation of truncated
TbR-I (Liu et al., 2009). However, unlike ADAM9, ectopic expres-
sion of ADAM17 in HEK293 cells expressing FGFR2 did not
generate the truncated FGFR2 fragment (Figure S3B). Although
ADAM9 has substrates other than FGFR2, the calvarial pheno-
types in Mmp14/ mice are likely largely FGFR2 signaling
related, given the critical role of FGFR signaling in calvarial
osteogenesis. It would be interesting to investigate in the future
if restoring FGFR2 signaling alone could rescue calvarial pheno-
types in MT1-MMP null mice.
In addition to ADAM9-dependent mechanism, MT1-MMP-
dependent but ADAM9-independentmechanisms, such as carti-
lage persistence and inadequate collagen degradation, may also
contribute to the overall calvarial phenotypes in MT1-MMP
mutant mice, especially in postnatal development. Early reports
by Holmbeck et al. (1999, 2003) and Zhou et al. (2000) have
revealed an essential role of MT1-MMP in skeletal development.
The calvarial bone defects were found at postnatal stage in
Mmp14/ mice in both C57BL/6 (Zhou et al., 2000) and 129
Rej/NIH Swiss black (Holmbeck et al., 1999) backgrounds. In
this study, calvarial defects in Mmp14/ mutants were found
to start as early as E15.5 dpc, which explained the calvarial
phenotypes observed in Mmp14/ mutants at birth. Sustained
cartilage primordium under the parietals and partially rescuedental Cell 22, 1176–1190, June 12, 2012 ª2012 Elsevier Inc. 1187
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and S6) suggested that MT1-MMP-mediated cartilage removal
and collagen degradation are required for calvarial bone growth
during postnatal development. Meanwhile, it also indicated
that MT1-MMP-regulated FGFR2 signaling plays a critical role
in the calvarial bone formation, especially during embryonic
development, because the loss of Adam9 restored FGFR2
signaling and largely rescued the calvarial defects inMmp14/
embryos (Figure 7). These data suggest that MT1-MMP
contributes to calvarial bone development through distinct
mechanisms, e.g., ADAM9-FGFR2-dependent and ADAM9-
FGFR2-independent mechanism. The latter one involves
collagen degradation and cartilage removal that likely have a
less significant role than ADAM9-FGFR2-dependent mechanism
in calvarial osteogenesis during embryonic development. The
postnatal defect of calvarial growth inMmp14/mice, however,
is likely attributable to both ADAM9-FGFR2 axis-dependent
defective osteoblast proliferation and ADAM9-FGFR2 axis-
independent yet MT1-MMP-dependent inadequate cartilage
removal and collagen degradation. In this regard, our data
were in line with previous work and provided further evidence
that collagen removal by MT1-MMP is important for calvarial
bone growth during postnatal development.
Mmp14/ calvarial osteoblasts exhibited specific defect in
response to FGF signaling that was completely restored when
Adam9 is depleted (Figure 7), suggesting that the defective
FGF signaling in Mmp14/-deficient mice is the consequence
of uncontrolled ADAM9 activity and increased FGFR2 shedding.
Although other ADAMs, such as ADAM15, have also been shown
to shed FGFR2 (Maretzky et al., 2009a, 2009b), the great reduc-
tion in truncated FGFR2 fragment and complete restoration of
ERK1/2 phosphorylation in Mmp14//Adam9/ osteoblasts
suggest that the cell surface ADAM9 is likely the predominant
sheddase of FGFR2 in calvarial osteoblasts.
Our study demonstrates that MT1-MMP facilitates the inacti-
vation of ADAM9 on cell surface, though it has been long known
to activate some MMPs such as pro-MMP2 and proMMP13.
MT1-MMP therefore serves as amaster modulator of proteolysis
that regulates the activities of a variety of pericellular metallopro-
teinases in different manners. Because ADAM9 has a broad
spectrum of substrates, loss of MT1-MMP would result in a
more complicated consequence than just deficient in collagen
degradation. Loss ofMT1-MMPmay affectmultiple downstream
targets of ADAM9. It is conceivable that upregulated ADAM9
in the absence of MT1-MMP may cause profound yet variable
consequences in different tissues attributable to different
signaling defects. The defective calvarial osteogenesis in
Mmp14/ mice is attributable, to large extent, to the compro-
mised FGFR2 signaling due to upregulated ADAM9 activity
(Figure 7) because FGF signaling in calvarial osteoblasts from
Mmp14/ mice is specifically compromised. However, we
could not exclude the possibility that ADAM9 downstream
targets other than FGFR2 may also play roles in the calvarial
defects in MT1-MMP-deficient mice. In this regard, it would be
interesting to investigate whether increased ADAM9 activity
also accounts for other developmental defects in Mmp14/
mice, such as angiogenesis, adipogenesis, and branching
morphogenesis. If so, which specific signaling is responsible
for the defect in a particular tissue? Interestingly, loss of1188 Developmental Cell 22, 1176–1190, June 12, 2012 ª2012 ElsevAdam9 does not extend the life span of Mmp14/ mice signifi-
cantly, suggesting that the premature deathmay not be a conse-
quence of upregulated ADAM9 activity.
In summary, our data suggest that MT1-MMP serves as
a master protease, and its functional depletion results in
a cascade of signaling abnormally mediated by ADAM9 activa-
tion, leading to profound developmental consequences. The
link between the MT1-MMP and FGF signaling through ADAM9
provides a paradigm for the regulation of growth factor signaling.
This study not only reveals the molecular mechanism underlying
defective calvarial development in Mmp14/ mice but also
provides important insights into the interplay among MT1-
MMP, FGFRs, and ADAMs in development and likely in various
pathological conditions as well.
EXPERIMENTAL PROCEDURES
Skeletal Preparation
The skull was dissected, and the brain and skin were removed. The calvariae
were stained with staining solution (0.015% w/v Alcian blue 8GX, 0.005%
w/v alizarin red S, 5% glacial acetic acid, 85% EtOH) for 10 days, followed
by rinsing and clearing with solution of 20% glycerol, 1% KOH at 37C
for 16 hr. Images of calvarial preparation were captured by Leica
stereomicroscope.
Ex Vivo Calvaria Culture
In vitro calvaria culture was performed as previously described (Kim et al.,
1998). In brief, calvariae were dissected from 15.5 dpc mouse fetus. The over-
lying skin and the brain were removed, and the calvaria explants were cultured
on 0.4 mm Culture plate insert (Millicell-CM) in a 6-well plate with DMEM, 10%
FBS, 100 mg/ml of vitamin C, and 100 mg/ml of Fungizone in 37C CO2
incubator. Heparin beads (Sigma-Aldrich) soaked with DMEM or rhFGF2
(30 ng/ml; R&D) were placed on the parietal bones. Images were captured
every 24 hr with a stereomicroscope.
Cell Surface Biotinylation
Experiment was performed by Cell Surface labeling Kit (Pierce) as previously
described (Liu et al., 2009). Briefly, cells were washed with ice-cold PBS and
incubated with EZ-link Sulfo-NHS-Biotin (1 mg/ml in PBS). Biotinylation was
stopped by quenching buffer, and the biotinylated proteins in cell lysate
were precipitated by NeutrAvidin beads, eluted by boiling, and subject to
western blotting. Other materials and experimental procedures, including
mice, antibodies, cell culture, immunofluorescence, RISH, reverse-transcrip-
tion PCR, and siRNA sequences, are included in Supplemental Experimental
Procedures.
Statistical Analyses
Data are represented as average ± SEM. The statistical analysis was per-
formed by Student’s t test, and p value <0.05 was considered statistically
significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and Supplemental Experimental
Procedures and can be found with this article online at doi:10.1016/j.devcel.
2012.04.014.
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